Eight international teams developing new biomedical technologies for a range of medical challenges
- Teams begin six-month innovation training and project mentoring from innovators at MIT and other leading institutions
- New technologies for a range of urgent medical needs, including heart attack recovery, acute brain injury, glaucoma, and tooth decay, among others
CAMBRIDGE, MASSACHUSETTS, 19 NOVEMBER 2026—MIT linQ, an international biomedical technology innovation consortium based in the Massachusetts Institute of Technology Institute for Medical Engineering and Sciences (MIT IMES), introduced the eight teams admitted to IDEA2 2027. The six-month program provides intensive innovation method training, collaborative project development, team-specific mentoring, and expertise to help projects move from novel ideas toward real-world application.
“Our 2027 cohort represents a new generation of biomedical technology innovators,” said Dr. Mercedes Balcells-Camps, Program Chair of IDEA² and a Principal Research Scientist at MIT. “Many of these teams are at the very start of their journey, which is exactly when mentoring makes the biggest difference. They bring fresh ideas to important problems that patients and caregivers face today, and they have the chance to shape their solutions around real needs from day one.”
Proposals for IDEA2 were invited from anywhere in the world, and selected teams come from the United States, Mexico, Argentina, Chile, Portugal, Spain, Italy, and South Africa. The projects selected for 2027 are:
- Amnova Biotech: Injectable regenerative hydrogel to repair heart tissue and prevent heart failure after a heart attack.
- DAISY: A new MRI encoding and decoding approach that enables imaging with open, planar magnets.
- FASTer: Portable, minimally invasive device to limit neurological injury after acute brain injury, before patients reach the hospital.
- iECG: Cable-free cardiac monitoring with AI-powered automated arrhythmia detection.
- MELX: Ambient sensing for behavioral health centers, residential addiction treatment, and senior facilities.
- OCTai: Interpretable AI that forecasts individual glaucoma progression risk from routine OCT scans and clinical data.
- Portalyze: A low-cost, traceable device for measuring portal pressure during endoscopic ultrasound in patients with cirrhosis.
- Thank You Floss: A unique approach to preventing cavities between teeth.
The teams were selected competitively for their potential impact and their readiness to benefit from mentoring. Through group innovation training and individualized mentorship and advising, they will sharpen their understanding of the clinical need, refine their research and development strategy, and plan their path toward patient impact.
Enterprise Mobility and Analog Devices return to IDEA² this year as program supporters, continuing a shared commitment to nurturing innovation with global impact. Dr. Martha Gray, Whitaker Professor in Biomedical Engineering at MIT and Director of MIT linQ, said, “The industry experience our supporters bring will serve these early-stage teams well, both during the program and in the years to come.”
The teams will meet in January at MIT for an initial workshop to sharpen the focus on the medical need they intend to address. They will then be matched with project mentors and subject and technology experts to help them develop their project over the winter and spring. In March and April, the teams will meet in workshops to report their progress, get new feedback from mentors and program alumni, and refine their project plans. Finally, in June they will gather to make their presentations of the progress in the program and make plans for next steps.
About IDEA2
IDEA² provides mentoring and connections to biomedical innovators around the world to develop their project ideas and to provide the expertise to realize them. It is especially valuable for trainees, early-stage professionals, and those who have few opportunities in their normal work to participate in innovation projects. More at http://idea2.mit.edu
About MIT linQ
MIT linQ is an initiative based in the Massachusetts Institute of Technology Institute for Medical Engineering and Sciences (MIT IMES) to develop a new paradigm for biomedical technology innovation. MIT linQ unifies a portfolio of international innovation programs focused on improving healthcare through need-driven, interdisciplinary research and training. For more information, visit http://linq.mit.edu


